PMID- 37113190
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230430
IS  - 1756-283X (Print)
IS  - 1756-2848 (Electronic)
IS  - 1756-283X (Linking)
VI  - 16
DP  - 2023
TI  - Incidence and type of adverse events in patients taking vonoprazan: A systematic 
      review and meta-analysis.
PG  - 17562848231167858
LID - 10.1177/17562848231167858 [doi]
LID - 17562848231167858
AB  - BACKGROUND: Vonoprazan, a novel acid-suppressive drug, is non-inferior to proton 
      pump inhibitors (PPIs) for the management of gastric acid-related diseases. 
      However, the safety of vonoprazan has not been systematically evaluated yet. 
      OBJECTIVES: To elucidate the incidence and type of adverse events (AEs) in 
      patients taking vonoprazan. DESIGN: Systematic review and meta-analysis. DATA 
      SOURCES AND METHODS: PubMed, EMBASE, and Cochrane Library databases were searched 
      for all studies reporting the safety of vonoprazan. The incidences of any AEs, 
      drug-related AEs, serious AEs, AEs leading to drug discontinuation, and common 
      AEs were pooled. Odds ratios (ORs) were calculated to compare the incidence of 
      AEs between patients taking vonoprazan and PPIs. RESULTS: Seventy-seven studies 
      were included. The pooled incidences of any AEs, drug-related AEs, serious AEs, 
      and AEs leading to drug discontinuation were 20, 7, 1, and 1%, respectively. The 
      incidences of any AEs (OR = 0.96, p = 0.66), drug-related AEs (OR = 1.10, 
      p = 0.44), serious AEs (OR = 1.14, p = 0.36), and AEs leading to drug 
      discontinuation (OR = 1.09, p = 0.55) were not significantly different between 
      patients taking vonoprazan and PPIs. In subgroup analyses, patients with peptic 
      ulcer disease (PUD) had higher incidences of any AEs, serious AEs, and AEs 
      leading to drug discontinuation than those with gastroesophageal reflux disease 
      (GERD), Helicobacter pylori (H. pylori) infection, and artificial ulcer after 
      gastric endoscopic submucosal dissection (ESD), but patients with H. pylori 
      infection had a higher incidence of drug-related AEs than those with PUD, GERD, 
      and artificial ulcer after gastric ESD. The incidence of AEs was higher in 
      patients taking long-term use of vonoprazan than those taking short-term use of 
      vonoprazan. CONCLUSION: Vonoprazan is well tolerated and shows similar safety 
      compared to PPIs. The safety of vonoprazan may be primarily influenced by its 
      indications and duration. REGISTRATION: PROSPERO CRD42022314982.
CI  - (c) The Author(s), 2023.
FAU - Xu, Wentao
AU  - Xu W
AUID- ORCID: 0000-0002-0156-791X
AD  - Department of Gastroenterology, General Hospital of Northern Theater Command, 
      Shenyang, China.
AD  - Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical 
      University, Shenyang, China.
FAU - Bai, Zhaohui
AU  - Bai Z
AUID- ORCID: 0000-0001-6206-7153
AD  - Department of Gastroenterology, General Hospital of Northern Theater Command, 
      Shenyang, China.
AD  - Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical 
      University, Shenyang, China.
FAU - Shang, Yiyang
AU  - Shang Y
AUID- ORCID: 0000-0003-3128-7991
AD  - Department of Gastroenterology, General Hospital of Northern Theater Command, 
      Shenyang, China.
AD  - Department of Life Sciences and Biopharmaceutics, Shenyang Pharmaceutical 
      University, Shenyang, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Gastroenterology, The 960th Hospital of the PLA, Jinan, China.
FAU - Wong, Yujun
AU  - Wong Y
AD  - Department of Gastroenterology and Hepatology, Changi General Hospital, 
      Singapore, Singapore.
FAU - Qi, Xingshun
AU  - Qi X
AUID- ORCID: 0000-0002-9448-6739
AD  - Department of Gastroenterology, General Hospital of Northern Theater Command, No. 
      83 Wenhua Road, Shenyang, Liaoning 110840, China.
LA  - eng
PT  - Journal Article
DEP - 20230420
PL  - England
TA  - Therap Adv Gastroenterol
JT  - Therapeutic advances in gastroenterology
JID - 101478893
PMC - PMC10126681
OTO - NOTNLM
OT  - adverse event
OT  - gastric acid
OT  - proton pump inhibitor
OT  - safety
OT  - vonoprazan
COIS- The authors declare that there is no conflict of interest.
EDAT- 2023/04/28 06:42
MHDA- 2023/04/28 06:43
PMCR- 2023/04/20
CRDT- 2023/04/28 02:24
PHST- 2022/11/15 00:00 [received]
PHST- 2023/03/20 00:00 [accepted]
PHST- 2023/04/28 06:43 [medline]
PHST- 2023/04/28 06:42 [pubmed]
PHST- 2023/04/28 02:24 [entrez]
PHST- 2023/04/20 00:00 [pmc-release]
AID - 10.1177_17562848231167858 [pii]
AID - 10.1177/17562848231167858 [doi]
PST - epublish
SO  - Therap Adv Gastroenterol. 2023 Apr 20;16:17562848231167858. doi: 
      10.1177/17562848231167858. eCollection 2023.